Subscribe
jeng-niamwhan-shutterstock-com
JENG_NIAMWHAN / Shutterstock.com
20 May 2015Americas

Gilead faces fresh Sovaldi challenge

Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi (sofosbuvir) in certain Asian, Latin American and European countries.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility